Clinical Trial Update: A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing the efficacy and safety of ribociclib in combination with endocrine therapy as adjuvant treatment for HR+/HER2- early breast cancer; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Early Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING